Portola Pharmaceuticals
Portola Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bleeding, with 2 trials.
Trial Pipeline
13 total, page 1 of 1
The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
NCT03397888
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT03310021
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT03083704
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT03330457
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT02220725
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT02207725
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT01758432
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
NCT03551730
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03218241
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
NCT01583218
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
NCT00984113
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
NCT00751231
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT00742859
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 3 |
Therapeutic Areas
What the Pipeline for Portola Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, Portola Pharmaceuticals is linked to 13 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 11 are already marked complete, representing roughly 85% of the total.
The phase mix for Portola Pharmaceuticals reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 10 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Portola Pharmaceuticals is Bleeding with 2 linked trials, and 2 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.